Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABUCCO: Neoadjuvant Ipilimumab and Nivolumab in Urothelial Carcinoma
NCT03387761Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ipilimumab and nivolumab in urothelial carcinoma (UC) (3 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Number of patients that had surgical resection <12 weeks after study start. Started Jan 2018; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03387761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387761.